Category Archives: Nanfang Hospital of Southern Medical University

Mesenchymal Stem Cell Injections and Hair Growth

Update: June 5, 2025

Combining Mesenchymal Stem Cells and Adenosine Triphosphate

Spain-based start-up Ideeea Therapeutics has raised €2.3 million in seed round funding (h/t “Alvaro”). The company’s AGAcell ® preclinical research program entails the treatment of androgenetic alopecia via the intradermal administration of a patented formulation. The latter consists of allogeneic mesenchymal stem cells (derived from adipose tissue) combined with a “bioactive molecule”.

Note that Dr. Eduardo López Bran (the lead scientist for this treatment) was interviewed on June 1. He is the head of the Dermatology Department at the San Carlos Clinical Hospital. He expects that human clinical trials could begin in 2027 or 2028, with an estimated duration of two years. The current research was conducted successfully in mice.

The bioactive molecule entails adenosine triphosphate (ATP). The combination of adipose derived stem cells and adenosine triphosphate regenerates hair via the regenerative capacity of the former and the cellular energy increase provided by the latter. Note that in 2024, I covered a Taiwanese company that is working on an AMPK activator product to boost ATP levels of human follicle dermal papilla cells. ATP sprays are often used during hair transplant procedures. And laser hair growth device energy also increases production of ATP.

December 26, 2024

Nanfang Hospital, Southern Medical University

In 2015, I discussed new hair multiplication related collaborative work between the University of Manitoba (Canada — led by Dr. Malcolm Xing) and Nanfang Hospital Southern Medical University (China). Researchers from the latter recently published two new hair related studies, one of which analyzes the results of Chinese clinical trials involving mesenchymal stem cell injections for hair growth.

Note that hair follicle derived mesenchymal stem cells (HF-MSCs) include both dermal papilla (DP) cells and dermal sheath (DS) cup cells. Mesenchymal stem cells can also be derived from: adult tissues (bone marrow, peripheral blood, adipose/fat and teeth); and neonatal-birth associated tissues (Wharton’s jelly, placenta, cord blood, umbilical cord and amniotic fluid).

In recent years, mesenchymal stem cells have been in the news a lot due to the rising popularity of mesenchymal stem cell (MSC)-derived exosomes in regenerative medicine applications.

Treating Androgenetic Alopecia with Mesenchymal Stem Cell Injections

Recently, reader “Theo” sent me a link to a new November 2024 study from the Department of Plastic and Aesthetic Surgery, Nanfang Hospital, Southern Medical University. It entails a superior method of isolating human hair follicle dermal papilla cells (DPCs).

More importantly, several of the co-authors of this study also co-authored a September 2024 study titled: “A Clinical Trial of Treating Androgenic Alopecia with Mesenchymal Stem Cell Suspension Derived from Autologous Hair Follicle.” This trial occurred at the Department of Plastic and Aesthetic Surgery, Nanfang Hospital, Southern Medical University (China). The link to the actual 50-person trial that ended in 2022 can be seen here.

Treating Androgenetic Alopecia with Stem Cell Injections
Treating Androgenetic Alopecia with Stem Cell Injections. Source: Plastic and Reconstructive Surgery, September 2024.

The results were encouraging, although the increasing hair count and hair thickening effects lasted for just 3 months. Note that at around 7 months, the treated group still had slightly higher terminal hair counts and mean hair diameters compared to when they started out. If this method is improved, a once-a-year injection session is totally fine by me.

“An increased proportion of terminal hair and hair shaft diameter was observed in the experimental group at 1 month. The effect lasted for 3 months. The hair-thickening effect of advanced miniaturized hair follicles with hair shaft diameter less than 60 µm was more notable than that for above 60 µm. No patient experienced any obvious side effects.”

Mesenchymal Stem Cell Injection Hair Growth
Mesenchymal Stem Cell Injection Hair Growth Increase. Source: Plastic and Reconstructive Surgery, September 2024.
Mesenchymal Stem Cell Injection Hair Diameter Increase
Mesenchymal Stem Cell Injection Hair Diameter Increase. Source: Plastic and Reconstructive Surgery, September 2024.

They also include two images showing before and after (3 months) hair growth results. The left side in the below image is the before photos.

Before and After Stem Cell Hair Growth
Before and After Stem Cell Hair Growth. Source: Plastic and Reconstructive Surgery, September 2024.

Stem Cells and Hair Multiplication

This makes me even more positive about Shiseido’s dermal sheath cup cell hair multiplication procedure that was released in 2024. And perhaps HairClone will finally test its dermal papilla cell injection treatment on humans in the UK in 2025. Also of note, in 2024, Dr. Junji Fukuda of Fukuda Lab announced that “Dermal papilla cell transplantation is about to begin in Japan.“

And several South Korean hair loss companies could test this in humans in 2025 too. In the past, Aderans (Japan) did the same with some success.

Note that similar attempts have been done in animals and humans in the past. Further reading:

In my 2015 interview with Dr. Xing, he said that he had just returned from a trip to Nanfang Hospital and that:

“A team of more than 10 clinical doctors is working on hair loss in the Department of Plastic Surgery, Nanfang Hospital.”

It is always great to see more hair related research and clinical trials taking place in China. Within East Asia, the country has lagged Japan and South Korea in importance when it comes to hair research.

Interview with Dr. Malcolm Xing

About one week ago, a very interesting article was published in the Journal of Materials Chemistry B. I managed to interview one of the lead scientists, Dr. Malcolm Xing.

Dermal Papilla Cell Delivery for Hair Regeneration

The title of this article was “Cytokine loaded layer-by-layer ultrathin matrices to deliver single dermal papilla cells for spot-by-spot hair follicle regeneration.” An easier to understand and more succinct title was postulated in an article in Chemistry Journal: “Re-seeding hairlines with stem cells.” I have always felt that the scalp is exactly like a garden and can be entirely reseeded in the future once scientists figure out the right method of doing so.

The approach to cure hair loss that was taken by this study’s authors is quite unique (see interview below for more on that). Moreover, this research entails a multinational collaboration between University of Manitoba, Canada (led by Dr. Malcolm Xing) and Nanfang Hospital Southern Medical University, China (led by Dr. Zhi-Qi Hu). Dr. Xing’s team’s tissueengineering website has not been updated for years.

I was happy to finally get news on hair loss research in China, a country that I have neglected in my Worldwide Hair Loss Research page. This is primarily due to language issues and my lack of motivation in trying to comb through Chinese search engines and social media.

I wanted to discuss this journal article last week, but was unsure about devoting a whole post to it. Then I decided to try my luck and see if either Dr. Xing or Dr. Hu were willing to conduct an interview with me via e-mail. Luckily Dr. Xing was willing, despite being on vacation this past week. I had to delay this post until he responded.

Please do not e-mail him yourself as he is probably swamped with inquiries related to this paper in addition to ongoing other research at his lab. You can post questions in the comments section of this post, and after a few days I will send them all to him in bulk. He has told me that he can reply to some more of my questions, but I am unwilling to bother him more than one more time.

Malcolm Xing
Dr. Malcolm Xing.

Interview with Dr. Malcolm Xing

Question 1) How applicable is your mouse model to a human model? Can you try this experiment on human dermal papilla cells without needing any official government approval (either in Canada or China or in both)?

Answer 1) Mouse model only provides us some primary support for further study in human cells and finally in a human model. No, we need official government approval.

Question 2) I assume you only worked on mice-to-mice DPC transplantation based on the image I saw of your work in Chemistry World magazine, but I have not read your whole paper as it is not yet publicly available on Google Scholar. Or did you also move human dermal papilla cells to mice?

Answer 2) Not yet for human dermal papilla cells.

Question 3) There has been an ever increasing amount of research done on dermal papilla cells in the hair loss world over the past few years e.g.,

Have you seen any work that is similar to yours? Any that is different, but that still interests you? Have you ever tried to collaborate with the Rendl lab?

Answer 3) Yes, there are similar works to ours. Only difference in what we did is just to give the dermal papilla cell very thin clothing for cellular function tuning. We didn’t get a chance to contact Dr. Rendl, but we are open to all kinds of collaboration.

Question 4 and 5) Dr. Jeff Biernaskie from Canada (see https://www.hairlosscure2020.com/the-university-of-calgary-hair-loss-research/) and a company called Replicel (Canada) have both done work on dermal sheath cup cells. Can you describe the difference in working with dermal sheath cup cells versus dermal papilla cells?

Why are some researchers focusing on the former, and some on the latter?

Answer 4) and 5) They are cellular biological based and we are biomaterials oriented. We are biomaterial engineers and study the hair regeneration from biomaterials and nanotechnology perspective to create a bioengineering microenvironment for cell growth.

[My note: Dr. Xing provided separate answers to my two related questions, but I it seems like he did not address the difference between choosing the dermal papilla versus dermal sheath cup cell areas of research. Perhaps there is not much difference there, and to be honest, I did not try to find out prior to asking that question].

Question 6) Have you had a chance to look at Dr. Colin Jahoda’s work (he has covered dermal papilla cells as far back as the early1980s)? He has recently coauthored a paper on 3D papilla spheroids and it seems like this is one way of restoring dermal papilla inductivity.

Your method of ‘nutritious nano-clothing’ seems like a totally different approach and perhaps has an even higher chance of success. However, I am not a scientist and can not differentiate between the work of all the researchers that I have mentioned in this e-mail thus far. Has your method ever been tried by other scientists? Do you think it is easier than what Dr. Jahoda is attempting?

Answer 6) Actually, Dr. Jahoda’s work gave us the inspiration for this study. In our another new work (to be submitted), we already combined currently published nano-clothing with 3D spheroids for hair regeneration. It’s very difficult for me to say which one is easier.
I enclosed several publications from our lab about nano-clothing and spheroids for tissue engineering.

Question 7 and 8) The ending of the article about your work in Chemistry World magazine has the following sentence: “Xing is currently trying to move the technology from the bench to the bedside.” What will it take to get this goal realized? Would you have to undergo clinical trials in a similar manner to the US (or in a similar manner to what Replicel is doing in Canada/Japan)?

If so, it would easily take five years, by which time I think a cure for hair loss will already be here. Replicel and its Japanese partner Shiseido themselves are approaching final clinical trials (in Japan, the government is speeding up the clinical trial process so many US companies are moving there to conduct final trials). Do you have confidence that your work can come to the bedside before the end of 2020? Would you need funding to get this work moving along?

Answer 7 and 8) Yes, we are trying to apply this trial in China. China has similar regulations to the US. Currently, several Chinese industry partners show their interests in collaborations. There potential partners have already biomedical products approved by China FDA. Right now, I am also looking forward to the industry collaboration from Canada.

Not sure for these final trials before the end of 2020, but we are working at this goal. Yes, we need funds from government and industry to move this application forward.

Question 9) How did you decide to include fibroblast growth factor-2 (FGF-2) in your experiment? There seem to be other fibroblast growth factors (e.g., FGF-1, FGF-7, FGF-10) that promote hair growth too, but I assume you preferred FGF-2)?

Answer 9) FGF-2 is the preferred growth factor from our clinic collaborator; however, we can put more than one GF in the nano-clothing.

Question 10) On my blog, I have a page listing key global centers of hair loss research. I have neglected research in China for the most part due to limited information availability. I only include centers/universities/labs that devote significant resources to hair loss research and are not just coming out with one hair loss research related study every few years.

Do you think that Nanfang Hospital of Southern Medical University in China has any department devoted to hair loss research? If you know of any other Chinese universities or institutions that are undertaking regular research on hair loss, please let me know and I will add it to my page on global centers of hair loss research.

Answer 10) As to my knowledge, a team of more than 10 clinical doctors is working on hair loss in the Department of Plastic Surgery, Nanfang Hospital. I just came back from that department for the collaboration when I got your email.

Question 11) On your tissue engineering website there is nothing about hair loss research, although the site has not been updated recently. How serious is your lab about hair loss research versus all the other types of tissue engineering research that you focus on?

Answer 11) We didn’t get the chance to update the web but we have more than 6 researchers work on this theme.

Thank you!